|
|
| Maladies Respiratoires > Etude de marché sectorielle |
| The World Asthma and COPD Treatment Market, 2006-2011: A Changing Market with Increasing Potential |
|
|
|
|
€ 2 219,00 |
Editeur
: |
Visiongain |
Langue
: |
Anglais |
Date de publication : |
Août 2006 |
Taille du document : |
137 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 61 pages | Août 2004 | Anglais
|
|
|
| Main
focus: |
asthma,copd,cold remedy,pharmaceutical,...
|
| Research
focus: |
market size and estimates,demand analysis, |
| Geographic
focus: |
usa,united kingdom,belgium,spain,australia |
| |
|
|
|
|
| 62 pages | Août 2004 | Anglais
|
|
|
| Main
focus: |
asthma,copd,cold remedy,pharmaceutical,...
|
| Research
focus: |
market size and estimates,demand analysis, |
| Geographic
focus: |
usa,united kingdom,belgium,spain |
| |
|
|
|
|
| 50 pages | Juin 2006 | Anglais
|
|
|
| Main
focus: |
asthma,copd,magazines,newspaper
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,austria |
| |
|
|
|
|
| 50 pages | Novembre 2004 | Français
|
|
|
| Main
focus: |
maladie respiratoire,fruit,fruits
|
| Research
focus: |
tendances et évolution du marché, |
| Geographic
focus: |
france,chine,inde,usa,madagascar,japon,réunion,... |
| |
|
|
|
|
| 43 pages | Juillet 2005 | Anglais
|
|
|
| Main
focus: |
asthma,respiratory disease,hospital,emergency,...
|
| Research
focus: |
economy outlook,market segmentation,market outlook, |
| Geographic
focus: |
australia,usa,netherlands |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
US State Market Index: Drugs acting on the respiratory system
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Drugs acting on the respiratory system [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 29 |
475,00 €
|
| |
| |
US Cough, Cold & Throat Remedies 2005
15 pages | Juin 2005 |
Snapdata's US Cough, Cold & Throat Remedies 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough cold an |
240,00 €
|
| |
| |
OTC Cough and Cold Remedies in France
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in France' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
Japan Pharmaceuticals 2004
12 pages | Décembre 2004 |
Snapdata's Japan Pharmaceuticals 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the Japanese pharmaceutical mar |
240,00 €
|
| |
| |
Partneringreview 2006 Vol 2 Ch 7: Respiratory (PR06V2C07)
112 pages | Février 2006 |
Partneringreview 2006 – Therapy area Respiratory provides an in depth view into the respiratory disease focused deals and alliances announced in 2005, in a clear and accessible format.
The report |
795,00 €
|
| |
| |
US Cough Syrup 2005
13 pages | Juin 2005 |
Snapdata's US Cough Syrup 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US cough syrup market, and covers |
240,00 €
|
| |
| |
UK Cough Cold & Throat Remedies 2004
12 pages | Juillet 2004 |
Snapdata's UK Cough Cold & Throat Remedies 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the UK cough, cold an |
240,00 €
|
| |
| |
Partneringreview 2006 – Therapy area (volume 2)
1802 pages | Février 2006 |
Partneringreview 2006 – Volume 2: Therapy area provides an in depth view into the deals and alliances by therapeutic area announced in 2005, in a clear and accessible format.
The report reviews ove |
2 295,00 €
|
| |
| |
OTC Cough and Cold Remedies in the United Kingdom
10 pages | Juin 2005 |
Euromonitor International’s ‘OTC Cough and Cold Remedies in the UK' Major Market Profile report offers an introduction to the market.
It is c.
10 pages long and provides a top line overview of |
198,00 €
|
| |
| |
Respiratory Care Equipment & Supplies
599 pages | Août 2005 |
This report analyzes the worldwide markets for Respiratory Care Equipment & Supplies in Millions of US$.
The specific product segments analyzed are Pulmonary Function Testing, Spirometers, Sleep Ap |
3 091,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The World Asthma and COPD Treatment Market, 2006-2011: A Changing Market with Increasing Potential |
|
|
VISIONGAIN’S LATEST REPORT – ORDER YOUR COPY TODAY
The asthma treatment market is a $15 billion market, driven by an increasing prevalence and yet without a treatment to cure this debilitating disease. All current drugs treat the symptoms but not the underlying cause. It is currently dominated by GSK with its $5.5 billion blockbuster, Advair/Seretide. However, this combination treatment is about to have its first real competition with Symbicort approved for the US market in July 2006. Combination drugs appear likely to dominate the mid-term forecast period as assessed by visiongain.
Pivotal Period
However, a closer look at the potential for this market sees an approaching pivotal period, which could well see considerable change as well as additional growth. New companies are developing products with novel modes of action. The monoclonal antibodies, for so long heralded as the most significant advance the pharmaceutical industry has developed in a number of years, appear to be ready to fulfill their potential in the asthma market.
Concern
Yet there are concerns. There is currently only one available mAb for asthma treatment – Xolair. It is more expensive than other asthma drugs and is only used for patients who have difficult to control asthma. Yet the standard drug treatments are also under examination. Concern over the overuse of steroid treatments has been compounded by recent revelations of possible safety concerns over the long-term use of beta-2 agonist reliever treatments.
The dominant company in this market is GSK but it may see its position slip as new drug treatments enter the market.
Why you should buy this report:
The asthma treatment market is large and is set to grow further.
Generic competition is already having an impact and will having further impetus after the market-leading drug Advair/Seretide loses patent protection in 2008.
By the end of the forecast period the leading companies will be competing with novel products.
Monoclonal antibodies look set to achieve their potential in a market that has significant unmet needs.
Leading drugs in the principal R&D based company pipelines are assessed.
This report considers the latest financial and anecdotal information to enable the most appropriate choice of strategy for this market.
|
|
The World Asthma and COPD Treatment Market, 2006-2011: A Changing Market with Increasing Potential
|
|
|
PPLSEN
|
|
|
|
|
